Inclisiran,Evolocumab
novartis,alnylam,amgen
['novartis']
novartis presents new data at #aha22 showing long-term sustained efficacy over a 4-year study of ldl-c lowering treatment. #novartisnews
The official account for @Novartis News & Media Updates. For media inquiries: media.relations@novartis.com. See our community guidelines: https://t.co/b4Kyh4UvNm